Serum cystatin C and prediabetes in non-obese US adults
详细信息 查看全文
- 作者：Charumathi Sabanayagam (1) (2) (3)
Tien Yin Wong (2) (3)
Jie Xiao (4)
Anoop Shankar (4) - 关键词：Cystatin C ; Prediabetes ; NHANES ; Gender ; Ethnicity
- 刊名：European Journal of Epidemiology
- 出版年：2013
- 出版时间：April 2013
- 年：2013
- 卷：28
- 期：4
- 页码：311-316
- 全文大小：180KB
- 参考文献：1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-66.
2. Fox CS, Larson MG, Leip EP, Meigs JB, Wilson PW, Levy D. Glycemic status and development of kidney disease: the Framingham Heart Study. Diabetes Care. 2005;28:2436-0. class="external" href="http://dx.doi.org/10.2337/diacare.28.10.2436">CrossRef
3. Mussap M, Dalla VM, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int. 2002;61:1453-1. class="external" href="http://dx.doi.org/10.1046/j.1523-1755.2002.00253.x">CrossRef
4. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis. 2000;36:29-4. class="external" href="http://dx.doi.org/10.1053/ajkd.2000.8237">CrossRef
5. Jeon YK, Kim MR, Huh JE, et al. Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. J Korean Med Sci. 2011;26:258-3. class="external" href="http://dx.doi.org/10.3346/jkms.2011.26.2.258">CrossRef
6. Willems D, Wolff F, Mekahli F, Gillet C. Cystatin C for early detection of renal impairment in diabetes. Clin Biochem. 2009;42:108-0. class="external" href="http://dx.doi.org/10.1016/j.clinbiochem.2008.10.002">CrossRef
7. Sahakyan K, Lee KE, Shankar A, Klein R. Serum cystatin C and the incidence of type 2 diabetes mellitus. Diabetologia. 2011;54:1335-0. class="external" href="http://dx.doi.org/10.1007/s00125-011-2096-6">CrossRef
8. American Diabetes Association. Standards of medical care in diabetes-010. Diabetes Care. 2010;33 Suppl 1:S11-1.
9. Cowie CC, Rust KF, Ford ES, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-994 and 2005-006. Diabetes Care. 2009;32:287-4. class="external" href="http://dx.doi.org/10.2337/dc08-1296">CrossRef
10. Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmochowski J, Trevisan M. Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care. 2007;30:1724-. class="external" href="http://dx.doi.org/10.2337/dc07-0040">CrossRef
11. Lafarge JC, Naour N, Clement K, Guerre-Millo M. Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie. 2010;92:1580-. class="external" href="http://dx.doi.org/10.1016/j.biochi.2010.04.011">CrossRef
12. Young JA, Hwang SJ, Sarnak MJ, et al. Association of visceral and subcutaneous adiposity with kidney function. Clin J Am Soc Nephrol. 2008;3:1786-1. class="external" href="http://dx.doi.org/10.2215/CJN.02490508">CrossRef
13. Shankar A, Teppala S. Relationship between body mass index and high cystatin levels among US adults. J Clin Hypertens (Greenwich). 2011;13:925-0. class="external" href="http://dx.doi.org/10.1111/j.1751-7176.2011.00548.x">CrossRef
14. National Center for Health Statistics. The National Health and Nutrition Examination Survey 1999-000: Survey Operations Manuals, Brochures, Consent Documents. Available at: cdc.gov/nchs/nhanes/nhanes1999-2000/current_nhanes99_00.htm" class="a-plus-plus">http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/current_nhanes99_00.htm
15. National Center for Health Statistics. The National Health and Nutrition Examination Survey 2001-002: Survey Operations Manuals, Brochures, Consent Documents. Available at: cdc.gov/nchs/nhanes/nhanes2001-2002/current_nhanes_01_02.htm" class="a-plus-plus">http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/current_nhanes_01_02.htm
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34 Suppl 1:S62-.
17. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem. 1997;43:1016-2.
18. Newman DJ. Cystatin C. Ann Clin Biochem. 2002;39:89-04. class="external" href="http://dx.doi.org/10.1258/0004563021901847">CrossRef
19. National Center for Health Statistics. Laboratory procedures used for NHANES 1999-000. Available at: cdc.gov/nchs/nhanes/nhanes1999-2000/lab99_00.htm" class="a-plus-plus">http://www.cdc.gov/nchs/nhanes/nhanes1999-2000/lab99_00.htm (2008). Accessed 25 Feb 2011.
20. National Center for Health Statistics. Laboratory procedures used for NHANES 2001-002. Available at: cdc.gov/nchs/nhanes/nhanes2001-2002/lab01_02.htm" class="a-plus-plus">http://www.cdc.gov/nchs/nhanes/nhanes2001-2002/lab01_02.htm (2008). Accessed 25 Feb 2011.
21. Selvin E, Manzi J, Stevens LA, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-994, 1999-004. Am J Kidney Dis. 2007;50:918-6. class="external" href="http://dx.doi.org/10.1053/j.ajkd.2007.08.020">CrossRef
22. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function—a review. Clin Chem Lab Med. 1999;37:389-5. class="external" href="http://dx.doi.org/10.1515/CCLM.1999.064">CrossRef
23. Shlipak MG, Praught ML, Sarnak MJ. Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens. 2006;15:270-. class="external" href="http://dx.doi.org/10.1097/01.mnh.0000222694.07336.92">CrossRef
24. Alehagen U, Dahlstrom U, Lindahl TL. Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur J Heart Fail. 2009;11:354-0. class="external" href="http://dx.doi.org/10.1093/eurjhf/hfp024">CrossRef
25. Ristiniemi N, Lund J, Tertti R, et al. Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome. Clin Biochem. 2012;45:535-0. class="external" href="http://dx.doi.org/10.1016/j.clinbiochem.2012.02.012">CrossRef
26. Harmoinen AP, Kouri TT, Wirta OR, et al. Evaluation of plasma cystatin C as a marker for glomerular filtration rate in patients with type 2 diabetes. Clin Nephrol. 1999;52:363-0.
27. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard BC. Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med. 2008;121:426-2. class="external" href="http://dx.doi.org/10.1016/j.amjmed.2008.01.040">CrossRef
28. Lee SH, Park SA, Ko SH, et al. Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. Metabolism. 2010;59:241-. class="external" href="http://dx.doi.org/10.1016/j.metabol.2009.07.019">CrossRef
29. Shlipak MG, Katz R, Cushman M, et al. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005;118:1416. class="external" href="http://dx.doi.org/10.1016/j.amjmed.2005.07.060">CrossRef
30. Leung-Tack J, Tavera C, Martinez J, Colle A. Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation. 1990;14:247-8. class="external" href="http://dx.doi.org/10.1007/BF00915809">CrossRef
31. Reffelmann T, Krebs A, Ittermann T, et al. Mild renal dysfunction as a non-traditional cardiovascular risk factor?-Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation. Atherosclerosis. 2010;211:660-. class="external" href="http://dx.doi.org/10.1016/j.atherosclerosis.2010.03.023">CrossRef
32. Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M. Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care. 2007;30:354-. class="external" href="http://dx.doi.org/10.2337/dc06-1772">CrossRef
33. Thorand B, Baumert J, Kolb H, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-002. Diabetes Care. 2007;30:854-0. class="external" href="http://dx.doi.org/10.2337/dc06-1693">CrossRef - 作者单位：Charumathi Sabanayagam (1) (2) (3)
Tien Yin Wong (2) (3)
Jie Xiao (4)
Anoop Shankar (4)
1. Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore, Singapore
2. Singapore Eye Research Institute, 11 Third Hospital Avenue, #06-3, SNEC Bldg, Singapore, 168751, Singapore
3. Department of Ophthalmology, National University of Singapore, Singapore, Singapore
4. Department of Community Medicine, West Virginia University School of Medicine, Morgantown, WV, USA - ISSN：1573-7284
文摘
Diabetes mellitus is the leading cause of end stage renal disease. Cystatin C, a marker of early renal impairment has been shown to be associated with diabetes. However, it is not clear if cystatin C is associated with prediabetes, an early stage in the hyperglycemic continuum where prevention efforts have been shown to be effective in delaying or preventing the onset of diabetes. We examined 2,033 participants from the National Health and Nutrition Examination Survey 1999-002, aged ?0?years (female 47.2?%) who were free of diabetes mellitus, chronic kidney disease and with body mass index <30?kg/m2. Prediabetes (n?=?541) was defined as a 2-h glucose concentration of 140-99?mg/dL, or a fasting glucose concentration of 110-25?mg/dL, or an A1C value of 5.7-.4?%. Cystatin C levels were categorized into gender-specific quartiles for analysis. Elevated levels of serum cystatin C were associated with prediabetes after adjusting for potential confounders including serum total cholesterol, systolic blood pressure, body mass index and C-reactive protein. Compared to those with cystatin C in the lowest quartile, the multivariable odds ratio (95?% confidence interval) of prediabetes among those in the highest quartile was 2.08 (1.09-.97), p for trend?=?0.02. Although, this association was stronger among women and non-Hispanic whites, there was no significant interaction by sex (p?=?0.1) or by race-ethnicity (p?=?0.6). Our findings suggest that elevated levels of serum cystatin C are associated with prediabetes in a nationally representative sample of non-obese US adults.